OncoLab has been selected for the TIPS follow-up program (Commercialization & Global Marketing), securing USD 200,000 in research and business development support.
The ANGel platform developed by OncoLab is a novel immuno-oncology technology that conjugates antibodies on the particle surface while encapsulating small molecules inside. Through this unique structure, ANGel achieves precise targeting, sustained efficacy, and the potential for personalized cancer treatment.
With this support, OncoLab will accelerate preparations for GLP preclinical studies and clinical entry, establish a robust CMC and quality control (QC) foundation, and strengthen global marketing strategies to expand clinical development and international partnerships.